Cell line · CVCL_0021
Papers213
2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
61 to 80 of 213
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| DAP12-associated synthetic antigen receptors enable multi-targeting of T cells with independent chimeric receptors in a small genetic payload. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Transcriptome-wide analysis of circRNA and RBP profiles and their molecular relevance for GBM. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The LINC01315-encoded small protein YAPer-ORF competes with PRP4k to hijack YAP signaling to aberrantly promote cell growth. | Cell Death Differ | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Glioblastoma-derived migrasomes promote migration and invasion by releasing PAK4 and LAMA4. | Commun Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting macrophage circadian rhythms with microcurrent stimulation to activate cancer immunity through phagocytic defense. | Theranostics | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Adenoviral delivery of the CIITA transgene induces T-cell-mediated killing in glioblastoma organoids. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Role of Sodium-Dependent Vitamin C Transporter-2 and Ascorbate in Regulating the Hypoxic Pathway in Cultured Glioblastoma Cells. | J Cell Biochem | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Functional loss of ERBB receptor feedback inhibitor 1 (MIG6) promotes glioblastoma tumorigenesis by aberrant activation of epidermal growth factor receptor (EGFR). | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The role of VANGL2 in glioma oncogenesis and progression: insights into expression profiles and prognostic relevance. | Front Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Rapid and reproducible generation of glioblastoma spheroids for high-throughput drug screening. | Front Bioeng Biotechnol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Prion protein regulates invasiveness in glioblastoma stem cells. | BMC Cancer | 2024 | Its Methods give the RRID and name the line | PubMed | |
| SLNP-based CDK4- targeted nanotherapy against glioblastoma. | Front Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CD97 maintains tumorigenicity of glioblastoma stem cells via mTORC2 signaling and is targeted by CAR Th9 cells. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma. | Int J Mol Sci | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Conversion of glioma cells into neuron-like cells by small molecules. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Neurons enhance blood-brain barrier function via upregulating claudin-5 and VE-cadherin expression due to glial cell line-derived neurotrophic factor secretion. | Elife | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CEP192 localises mitotic Aurora-A activity by priming its interaction with TPX2. | EMBO J | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Molecular subtypes based on immunologic and epithelial-mesenchymal transition gene sets reveal tumor immune microenvironment characteristics and implications for immunotherapy of patients with glioma. | Heliyon | 2024 | Its Methods give the RRID and name the line | PubMed | |
| mLumiOpto Is a Mitochondrial-Targeted Gene Therapy for Treating Cancer. | Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0021/papers?page=4